Acute Kidney Injury

Acute kidney injury (AKI) is a clinical syndrome characterized by a rapid (within hours to days) deterioration of renal function, resulting in the inability of the kidneys to maintain fluid, electrolyte, and acid-base homeostasis, and to excrete nitrogenous wastes. In veterinary medicine, AKI encompasses a spectrum of severity from mild, subclinical injury (detectable only by sensitive biomarkers) to severe, life-threatening renal failure requiring intensive care and often renal replacement therapy. The condition is classified according to the International Renal Interest Society (IRIS) AKI grading scheme, which stages patients based on serum creatinine concentration, urine output, and clinical signs. AKI can be prerenal (due to decreased renal perfusion), intrinsic renal (due to damage to the renal parenchyma, particularly the tubules), or postrenal (due to obstruction of urine outflow). Intrinsic renal AKI is the most common form in small animals, with acute tubular injury (ATI) being the predominant histopathologic lesion. The syndrome is associated with high morbidity and mortality, and early recognition and intervention are critical for optimizing outcomes.

The etiologies of AKI in dogs and cats are numerous and can be categorized into prerenal, intrinsic renal, and postrenal causes. Prerenal AKI results from severe hypoperfusion of the kidneys, which can be due to hypovolemia (e.g., hemorrhage, severe dehydration, burns), hypotension (e.g., septic shock, anaphylaxis, cardiac failure), or decreased effective circulating volume (e.g., hypoalbuminemia, vasodilation). Intrinsic renal AKI is most commonly caused by acute tubular injury (ATI) from nephrotoxins or ischemia. Nephrotoxins include: (1) nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, and carprofen, which inhibit cyclooxygenase and reduce renal prostaglandin synthesis, leading to vasoconstriction and medullary ischemia; (2) aminoglycoside antibiotics (e.g., gentamicin, amikacin), which accumulate in proximal tubular cells and cause phospholipidosis and mitochondrial dysfunction; (3) amphotericin B, which causes direct tubular toxicity; (4) chemotherapeutic agents such as cisplatin and doxorubicin; (5) heavy metals (lead, mercury, thallium); (6) ethylene glycol (antifreeze), which is metabolized to glycolic acid and oxalate, causing severe metabolic acidosis and calcium oxalate crystal deposition in tubules; (7) lilies (Lilium and Hemerocallis species) in cats, which cause severe tubular necrosis; (8) grapes and raisins in dogs, which cause acute tubular necrosis; (9) vitamin D analogs (e.g., cholecalciferol rodenticides), leading to hypercalcemia and nephrocalcinosis; (10) snake venom (e.g., viperidae), which can cause direct nephrotoxicity and coagulopathy. Ischemic ATI can occur secondary to prolonged hypotension, hypovolemia, or thromboembolic events. Other intrinsic causes include acute glomerulonephritis (e.g., due to infectious agents such as Leptospira, Borrelia, or immune-mediated diseases), acute interstitial nephritis (e.g., drug-induced, infectious), and pyelonephritis (bacterial infection of the renal pelvis and parenchyma). Postrenal AKI is caused by obstruction of urine outflow, such as urethral obstruction (common in male cats with uroliths or plugs), ureteral obstruction (e.g., calculi, neoplasia), or rupture of the urinary tract. In addition, certain infectious agents can directly cause AKI, including Leptospira interrogans (in dogs), feline infectious peritonitis (FIP) virus, and bacterial pyelonephritis. Toxins such as ethylene glycol and lilies are common causes in emergency settings.

AKI occurs in both dogs and cats, with no strong breed or sex predilection overall, though certain breeds may be predisposed to specific etiologies. For example, dogs of any breed can develop leptospirosis, but it is more common in large-breed dogs with outdoor access, particularly in warm, humid climates. Cats are uniquely susceptible to lily toxicity, and any breed can be affected. Ethylene glycol toxicity is more common in dogs due to their indiscriminate ingestion habits, but cats are also at risk. Age distribution is bimodal: younger animals may be more prone to toxin exposure (e.g., ethylene glycol, lilies) and infectious causes, while older animals may have underlying chronic kidney disease (CKD) that predisposes them to AKI (acute-on-chronic). The incidence of AKI in veterinary practice is not precisely known, but it is a common emergency presentation. In a retrospective study of dogs with AKI, the most common causes were pyelonephritis, leptospirosis, and neoplasia. In cats, causes included ureteral obstruction, nephrotoxins (lilies, NSAIDs), and acute-on-chronic kidney disease. Mortality rates are high, ranging from 40% to 60% in dogs and cats with severe AKI, and are even higher in cases requiring dialysis. Geographic and seasonal variations exist: leptospirosis is more common in the autumn and in areas with high rainfall; ethylene glycol toxicity is more common in winter in colder climates due to antifreeze use.

The pathophysiology of AKI is complex and involves multiple interrelated mechanisms. In prerenal AKI, decreased renal blood flow leads to reduced glomerular filtration rate (GFR) and activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system, causing renal vasoconstriction and sodium and water retention. If hypoperfusion is prolonged, ischemic injury to the tubular epithelium ensues, particularly in the proximal tubules and medullary thick ascending limb, which are highly metabolically active and susceptible to hypoxia. Ischemic ATI is characterized by ATP depletion, loss of cell polarity, disruption of the actin cytoskeleton, and shedding of brush border membranes. This leads to tubular cell necrosis and apoptosis, with subsequent sloughing of cells into the tubular lumen, forming casts and causing intratubular obstruction. Backleak of glomerular filtrate through damaged tubular epithelium occurs, further reducing effective GFR. In nephrotoxic ATI, toxins directly damage tubular cells, often through oxidative stress, mitochondrial dysfunction, or interference with cellular transport. For example, aminoglycosides bind to megalin receptors on proximal tubular cells and are internalized, causing lysosomal phospholipidosis and cell death. Ethylene glycol metabolites cause severe metabolic acidosis and calcium oxalate crystal deposition, which obstructs tubules and causes direct cellular injury. In both ischemic and nephrotoxic ATI, an inflammatory response is triggered, with infiltration of neutrophils, macrophages, and lymphocytes, and release of pro-inflammatory cytokines (TNF-α, IL-1, IL-6), chemokines, and reactive oxygen species. This amplifies tubular injury and leads to endothelial activation, increased vascular permeability, and further reduction in renal blood flow. The renal medulla is particularly vulnerable to hypoxia due to its high oxygen demand and low oxygen tension. In addition, AKI leads to systemic effects, including fluid overload, electrolyte imbalances (hyperkalemia, hyperphosphatemia, hypocalcemia), metabolic acidosis, and uremia, which affect multiple organ systems. Uremic toxins accumulate, causing gastrointestinal signs (vomiting, diarrhea), neurological signs (depression, seizures), and immune dysfunction. The kidney also plays a role in erythropoietin production, so AKI can lead to anemia. In the recovery phase, surviving tubular cells undergo regeneration and repair, but if the injury is severe, fibrosis and progression to chronic kidney disease can occur.

Several factors predispose animals to AKI. Intrinsic factors include age (neonates and geriatrics have reduced renal reserve and altered drug metabolism), breed (e.g., Greyhounds may have lower GFR and be more sensitive to NSAIDs), and pre-existing chronic kidney disease (CKD), which reduces renal functional reserve and makes the kidneys more vulnerable to additional insults. Genetic factors may influence susceptibility to certain toxins; for example, some dogs may have polymorphisms in drug-metabolizing enzymes that increase the risk of aminoglycoside nephrotoxicity. Extrinsic factors include the use of nephrotoxic drugs (e.g., NSAIDs, aminoglycosides, amphotericin B), particularly in patients with dehydration, hypotension, or concurrent use of other nephrotoxic agents. Environmental exposure to toxins (ethylene glycol, lilies, grapes, rodenticides) is a major risk factor. Infectious agents, such as Leptospira, are more likely to cause AKI in unvaccinated or inadequately vaccinated dogs with outdoor access. Management factors include inadequate fluid therapy during surgery or illness, which can lead to prerenal azotemia and subsequent ATI. In cats, urethral obstruction is a common cause of postrenal AKI, and factors such as obesity, stress, and litter box hygiene may predispose to urinary obstruction. Additionally, animals with hypercalcemia, hyperbilirubinemia, or sepsis are at increased risk of AKI due to the effects of these conditions on renal perfusion and tubular function.

Clinical signs of AKI vary depending on the severity and stage of the disease. In the peracute phase (within hours), animals may present with signs of the underlying cause (e.g., ingestion of toxin, sepsis) and may have minimal renal-specific signs. As AKI progresses, clinical signs become more apparent. Common signs include depression, lethargy, anorexia, vomiting, diarrhea, and dehydration. Polyuria and polydipsia may be seen early in the course, especially in non-oliguric AKI, but oliguria or anuria can develop as the disease worsens. Physical examination may reveal pale mucous membranes, prolonged capillary refill time, weak pulses, and tachycardia if hypovolemia is present. In severe cases, bradycardia may occur due to hyperkalemia. Oral ulcerations, uremic breath, and gingivitis may be present. Abdominal palpation may reveal renomegaly or pain in the renal area, especially with pyelonephritis or obstruction. In postrenal AKI, a distended bladder may be palpable if urethral obstruction is present. Neurological signs such as weakness, tremors, seizures, or coma can occur due to uremic encephalopathy, metabolic acidosis, or electrolyte imbalances. In cats, lily toxicity may cause vomiting, hypersalivation, and depression within hours, followed by AKI signs within 24-72 hours. Ethylene glycol toxicity initially causes neurological signs (ataxia, depression) and vomiting, followed by severe metabolic acidosis and AKI. In the subacute and chronic phases, signs may include weight loss, poor hair coat, and persistent vomiting. Some animals may develop systemic hypertension, which can cause retinal detachment or blindness. In terminal stages, anuria, severe electrolyte disturbances, and uremic coma may occur.

The differential diagnoses for AKI include conditions that cause similar clinical signs or laboratory abnormalities. Key differentials include: (1) Chronic kidney disease (CKD): Differentiated by history of gradual weight loss, poor hair coat, small irregular kidneys on palpation or imaging, and non-regenerative anemia. Serum creatinine may be elevated, but there is often a history of polyuria/polydipsia for months. Renal ultrasonography may show reduced kidney size and increased echogenicity. (2) Prerenal azotemia: Caused by dehydration or hypovolemia; differentiated by history of fluid loss, physical findings of dehydration, and response to fluid therapy (azotemia resolves within 24-48 hours). Urine specific gravity is typically >1.030 in dogs and >1.035 in cats, and urine sediment is unremarkable. (3) Postrenal azotemia: Due to urinary obstruction or rupture; differentiated by history of anuria or stranguria, palpable distended bladder, or abdominal effusion. Imaging (radiography, ultrasonography) may reveal uroliths or bladder rupture. Serum creatinine and BUN are elevated, but urine output is decreased or absent. (4) Acute interstitial nephritis: Can be caused by drugs (e.g., penicillins, sulfonamides) or infections; may present with fever, flank pain, and eosinophilia. Renal biopsy may show interstitial inflammation. (5) Acute glomerulonephritis: Presents with proteinuria, hypoalbuminemia, and edema; may be associated with infectious or immune-mediated diseases. Urinalysis shows proteinuria and casts, and renal biopsy is diagnostic. (6) Pyelonephritis: Presents with fever, flank pain, and bacteriuria; urine culture is positive. Imaging may show renal pelvic dilation. (7) Leptospirosis: In dogs, presents with fever, icterus, myalgia, and AKI; diagnosis via serology (MAT) or PCR. (8) Feline infectious peritonitis (FIP): In cats, can cause granulomatous nephritis and AKI; diagnosis via histopathology, immunohistochemistry, or PCR on effusion. (9) Toxin exposure (e.g., ethylene glycol, lilies, grapes): History of exposure and characteristic clinical signs; specific tests (e.g., ethylene glycol levels, calcium oxalate crystals in urine) can confirm. (10) Neoplasia (e.g., lymphoma, renal carcinoma): May cause renomegaly and AKI; imaging and biopsy are diagnostic.

The diagnostic approach to AKI should be systematic and stepwise. 1. Initial triage and stabilization: Assess airway, breathing, and circulation. Obtain a thorough history, including possible toxin exposure, drug administration, and recent illnesses. Perform a complete physical examination, with special attention to hydration status, mucous membranes, heart rate, pulse quality, and abdominal palpation. 2. Baseline laboratory tests: Obtain a minimum database including packed cell volume (PCV), total solids (TS), blood glucose, blood urea nitrogen (BUN), creatinine, electrolytes (sodium, potassium, chloride), calcium, phosphorus, and acid-base status (venous blood gas). A complete blood count (CBC) and serum biochemistry panel should also be performed. 3. Urinalysis: Collect urine via cystocentesis or catheterization for urinalysis, including urine specific gravity (USG), dipstick, and sediment examination. In AKI, USG is often isosthenuric (1.008-1.012) or minimally concentrated (<1.030 in dogs, <1.035 in cats). Sediment may show casts (granular, cellular), renal epithelial cells, and crystals (e.g., calcium oxalate in ethylene glycol toxicity). Urine culture and sensitivity should be performed if pyelonephritis is suspected. 4. Imaging: Abdominal radiography may reveal renomegaly, radiopaque uroliths, or loss of abdominal detail. Abdominal ultrasonography is more sensitive and can assess kidney size, echogenicity, corticomedullary distinction, and the presence of hydronephrosis or perirenal fluid. Doppler ultrasound can evaluate renal blood flow. If obstruction is suspected, contrast studies (e.g., excretory urography) or computed tomography (CT) may be indicated. 5. Specific diagnostic tests: Based on history and clinical signs, test for specific etiologies. For leptospirosis, perform microscopic agglutination test (MAT) on paired sera or PCR on blood/urine. For ethylene glycol, measure serum ethylene glycol concentration (if available) or use a point-of-care test; also look for calcium oxalate crystals in urine. For lily toxicity, obtain history of exposure and monitor renal parameters. For suspected drug toxicity, review drug history. 6. Renal biopsy: If the cause remains unclear or if glomerular disease is suspected, a renal biopsy may be indicated. This is typically performed via ultrasound-guided needle biopsy or surgical biopsy. Histopathology can differentiate between tubular, interstitial, glomerular, and vascular lesions. 7. Staging: Use the IRIS AKI grading system to stage the severity of AKI based on serum creatinine concentration and urine output. Grade I: non-azotemic AKI with risk factors; Grade II: mild azotemia (creatinine 1.4-2.0 mg/dL in dogs, 1.6-2.5 mg/dL in cats) or urine output <1 ml/kg/h for >6 hours; Grade III: moderate azotemia (2.1-5.0 mg/dL in dogs, 2.6-5.0 mg/dL in cats) or urine output <1 ml/kg/h for >12 hours; Grade IV: severe azotemia (5.1-10.0 mg/dL) or urine output <0.5 ml/kg/h for >12 hours; Grade V: creatinine >10 mg/dL or anuria. This staging helps guide treatment and prognosis.

Laboratory findings in AKI are characteristic and reflect the loss of renal function. Hematology: The CBC may show hemoconcentration (increased PCV) if dehydration is present, or anemia if there is concurrent blood loss or hemolysis (e.g., leptospirosis). Leukocytosis may be present due to stress or infection. Serum biochemistry: BUN and creatinine are elevated, with creatinine being more specific for renal function. The magnitude of elevation correlates with the severity of AKI. Hyperphosphatemia is common due to decreased renal excretion. Calcium levels may be low (due to hyperphosphatemia and decreased vitamin D activation) or high (if vitamin D toxicosis or hypercalcemia is the cause). Potassium is often elevated, especially in oliguric/anuric AKI, due to decreased excretion and metabolic acidosis. Sodium may be low, normal, or high depending on hydration status. Chloride may be low due to vomiting. Blood gas analysis typically reveals metabolic acidosis (decreased pH, decreased bicarbonate) due to retention of organic acids and decreased renal acid excretion. Urinalysis: Urine specific gravity is often isosthenuric (1.008-1.012) or minimally concentrated (<1.030 in dogs, <1.035 in cats), indicating impaired renal concentrating ability. Proteinuria may be present, but it is usually mild unless glomerular disease is present. Urine sediment may contain granular or cellular casts, renal epithelial cells, and red blood cells. Calcium oxalate monohydrate crystals are highly suggestive of ethylene glycol toxicity. Urine culture should be performed if pyelonephritis is suspected. Specific biomarkers: Serum symmetric dimethylarginine (SDMA) is an early marker of decreased GFR and may be elevated before creatinine. Other biomarkers such as urinary neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and cystatin C are being evaluated in veterinary medicine but are not yet widely available. In cases of leptospirosis, serology (MAT) or PCR can confirm the diagnosis. In cases of suspected immune-mediated disease, antinuclear antibody (ANA) testing may be helpful.

Imaging plays a crucial role in the diagnosis and management of AKI. Abdominal radiography: May show renomegaly (enlarged kidneys) in acute disease, or small, irregular kidneys in chronic disease. Radiopaque uroliths (e.g., calcium oxalate, struvite) may be visible in the renal pelvis, ureters, or bladder. Loss of abdominal detail may indicate effusion or peritonitis. Abdominal ultrasonography: This is the most useful imaging modality. In AKI, the kidneys may be normal-sized or enlarged, with increased cortical echogenicity (due to tubular damage, inflammation, or fibrosis) and decreased corticomedullary distinction. The renal pelvis may be dilated if obstruction or pyelonephritis is present. Perirenal fluid may be seen in some cases. Doppler ultrasound can assess renal arterial blood flow and resistive index (RI), which may be elevated in AKI. Ultrasonography is also useful for guiding renal biopsy. Computed tomography (CT): CT with contrast can provide detailed assessment of renal perfusion, detect masses, and evaluate the ureters for obstruction. It is particularly useful in cases of suspected ureteral calculi or neoplasia. Magnetic resonance imaging (MRI): MRI is less commonly used but can provide detailed soft tissue contrast and may be helpful in evaluating renal masses or vascular abnormalities. Excretory urography: This contrast study can assess renal function and detect obstruction, but it is less commonly used due to the risk of contrast-induced nephropathy. In cases of postrenal AKI, imaging of the lower urinary tract (e.g., urethral obstruction) may be performed via radiography or ultrasonography.

Cytology and histopathology are important for diagnosing the underlying cause of AKI when it is not apparent from history and non-invasive tests. Fine needle aspiration (FNA) of the kidney may be performed under ultrasound guidance. Cytology may reveal inflammatory cells (neutrophils, lymphocytes, plasma cells) in cases of interstitial nephritis or pyelonephritis, or neoplastic cells in cases of renal lymphoma or carcinoma. However, FNA has limited diagnostic value for tubular injury and may be non-diagnostic. Histopathology from renal biopsy is the gold standard for diagnosing the underlying renal lesion. In acute tubular injury (ATI), histopathology shows tubular epithelial cell necrosis, sloughing of cells into the tubular lumen, cast formation, and interstitial edema. There may be evidence of regeneration, such as mitotic figures and flattened epithelial cells. In acute interstitial nephritis, there is infiltration of inflammatory cells (lymphocytes, plasma cells, neutrophils) into the interstitium, with variable tubular damage. In acute glomerulonephritis, there is hypercellularity of the glomeruli, thickening of the basement membrane, and possibly crescents. Special stains can help identify specific etiologies: calcium oxalate crystals (von Kossa stain) in ethylene glycol toxicity, leptospiral organisms (Warthin-Starry silver stain or immunohistochemistry) in leptospirosis, and immune complex deposition (immunofluorescence) in immune-mediated glomerulonephritis. Histopathology is also essential for diagnosing neoplasia. The biopsy should be performed by an experienced clinician, and the risk of hemorrhage or other complications must be weighed against the diagnostic benefit.

Treatment of AKI is multifaceted and should be initiated promptly. The goals are to correct prerenal factors, minimize further renal injury, manage complications, and support the animal until renal recovery occurs. 1. Emergency stabilization: Assess and stabilize the airway, breathing, and circulation. If the animal is in shock, administer intravenous fluids (crystalloids) at a shock dose (e.g., 15-20 ml/kg over 15-30 minutes in dogs, 10-15 ml/kg in cats) and reassess. 2. Fluid therapy: Once the animal is hemodynamically stable, fluid therapy should be tailored to the animal's hydration status and urine output. In non-oliguric AKI, maintain hydration with balanced crystalloids (e.g., lactated Ringer's solution) at a rate that replaces ongoing losses (e.g., 40-60 ml/kg/day in dogs, 30-50 ml/kg/day in cats) plus insensible losses. In oliguric/anuric AKI, fluid therapy must be carefully monitored to avoid fluid overload. Central venous pressure (CVP) and body weight should be monitored frequently. If oliguria persists despite adequate hydration, diuretics may be considered (see below). 3. Diuretics: Furosemide (2-4 mg/kg IV or SC, q8-12h) may be used to increase urine output, but it does not improve renal recovery and may worsen dehydration if not carefully managed. Mannitol (0.25-0.5 g/kg IV over 20 minutes) can be used to promote diuresis and reduce tubular obstruction, but it is contraindicated in anuric animals or those with volume overload. 4. Management of hyperkalemia: If serum potassium >5.5 mEq/L, administer 10% calcium gluconate (0.5-1.0 ml/kg IV over 10-20 minutes) to stabilize the myocardium, followed by insulin (0.1-0.2 U/kg IV) with dextrose (2 g per unit of insulin) to shift potassium intracellularly. Sodium bicarbonate (1-2 mEq/kg IV over 15-30 minutes) may be given if severe metabolic acidosis is present, but it should be used cautiously as it can worsen hypocalcemia. 5. Management of metabolic acidosis: If pH <7.2 or bicarbonate <12 mEq/L, administer sodium bicarbonate (0.5-1 mEq/kg IV over 30 minutes) with careful monitoring. 6. Management of uremia: Gastrointestinal protectants (e.g., omeprazole 0.5-1 mg/kg PO q12h, sucralfate 0.5-1 g PO q8h) may be used to reduce uremic gastritis. Antiemetics (e.g., maropitant 1 mg/kg SC q24h, ondansetron 0.5-1 mg/kg IV q12h) are indicated for vomiting. 7. Nutritional support: Provide a high-quality, low-protein diet (if not vomiting) to reduce nitrogenous waste production. If the animal is anorexic, consider placement of a feeding tube (e.g., nasoesophageal, esophagostomy) for enteral nutrition. 8. Specific therapies: If a specific cause is identified, treat accordingly. For leptospirosis, administer appropriate antibiotics (e.g., doxycycline 5 mg/kg PO q12h for 14 days, or ampicillin 20 mg/kg IV q8h for acute cases). For ethylene glycol toxicity, administer ethanol (20% solution, 5.5 ml/kg IV q6h for 5 treatments, then q8h for 4 treatments) or 4-methylpyrazole (fomepizole) (15 mg/kg IV initially, then 5 mg/kg at 12, 24, and 36 hours) if within 8-12 hours of ingestion. For lily toxicity in cats, aggressive fluid therapy and gastrointestinal decontamination (if within 6 hours) are essential. 9. Renal replacement therapy: In severe AKI that is refractory to medical management, hemodialysis or peritoneal dialysis may be indicated. Hemodialysis is the most effective method for removing uremic toxins and managing fluid overload, but it is only available at specialized referral centers. Peritoneal dialysis can be performed in general practice but is less efficient. 10. Monitoring: Monitor body weight, urine output, serum creatinine, BUN, electrolytes, and acid-base status frequently (at least every 12-24 hours initially). Adjust fluid therapy and medications accordingly.

The prognosis for AKI varies depending on the underlying cause, severity of injury, and response to treatment. Overall mortality rates are high, ranging from 40% to 60% in dogs and cats with severe AKI. Factors associated with a poorer prognosis include: oliguria or anuria at presentation, higher IRIS grade (IV or V), need for dialysis, presence of concurrent disease (e.g., sepsis, pancreatitis), and delayed initiation of treatment. Causes with a more favorable prognosis include those that are reversible, such as prerenal AKI, mild nephrotoxin exposure (if treated early), and pyelonephritis. Causes with a poorer prognosis include ethylene glycol toxicity (especially if treated late), lily toxicity in cats (if not treated within 18 hours), and severe ischemic injury. In animals that survive the acute phase, renal function may recover partially or completely, but some may progress to chronic kidney disease. Serial monitoring of serum creatinine and urine output is essential to assess recovery. If creatinine levels decrease and urine output normalizes within 3-7 days, the prognosis is better. However, even with recovery, there may be permanent loss of renal function, and long-term management may be needed.

Follow-up care for animals with AKI is critical to monitor recovery and manage complications. After discharge, recheck serum creatinine, BUN, electrolytes, and urinalysis at 1 week, 2 weeks, 1 month, and then every 3-6 months, depending on the severity of the initial injury. Blood pressure should be measured at each recheck, as hypertension can develop or worsen. If the animal has residual azotemia, a renal diet (low protein, low phosphorus) may be recommended. If the animal is on medications (e.g., antihypertensives, phosphate binders), adjust dosages based on renal function. Owners should be educated on the signs of AKI recurrence and the importance of avoiding nephrotoxic drugs (e.g., NSAIDs) in the future. If the underlying cause was infectious (e.g., leptospirosis), appropriate vaccination and preventive measures should be discussed. In animals that required dialysis, follow-up with a specialist is essential. Long-term monitoring may include serial SDMA measurements to detect early decline in GFR. If the animal develops chronic kidney disease, follow-up should be tailored to the IRIS CKD staging guidelines.

Pearls: 1. Early recognition is key: Monitor urine output and serum creatinine closely in any hospitalized patient at risk for AKI (e.g., those receiving nephrotoxic drugs, with sepsis, or undergoing surgery). 2. Urine specific gravity is a simple and valuable test: A USG >1.030 in a dog or >1.035 in a cat with azotemia suggests prerenal azotemia, while a USG <1.020 suggests intrinsic renal disease. 3. In oliguric AKI, a fluid challenge (e.g., 10-20 ml/kg IV over 30-60 minutes) can help differentiate prerenal from intrinsic AKI; if urine output does not increase, intrinsic AKI is likely. 4. Hyperkalemia is a life-threatening complication: Treat aggressively with calcium gluconate, insulin/dextrose, and bicarbonate if needed. 5. Avoid nephrotoxic drugs in animals with AKI: NSAIDs, aminoglycosides, and amphotericin B should be avoided or used with extreme caution. 6. In cats with suspected lily toxicity, initiate aggressive fluid therapy immediately, even before confirming exposure. 7. Consider leptospirosis in any dog with acute kidney injury and fever, especially if unvaccinated or with outdoor access. Pitfalls: 1. Do not administer mannitol to anuric animals or those with volume overload, as it can cause pulmonary edema. 2. Do not use furosemide as a sole treatment for oliguria without ensuring adequate hydration; it can worsen prerenal azotemia. 3. Do not delay dialysis if indicated; early referral to a dialysis center can improve outcomes. 4. Do not misinterpret a normal urine output as a sign of recovery; non-oliguric AKI can still have severe tubular damage. 5. Do not forget to monitor blood pressure; hypertension is common in AKI and can cause further renal damage. 6. Do not use sodium bicarbonate routinely for metabolic acidosis; it can cause hypernatremia and worsen hypocalcemia. 7. Do not overlook postrenal causes: Always check for urethral obstruction or bladder rupture in animals with anuria.

Drug protocols for AKI are based on Plumb's Veterinary Drug Handbook and current veterinary guidelines. 1. Fluid therapy: Balanced crystalloids (e.g., lactated Ringer's solution, Normosol-R) are the mainstay. For maintenance, use 40-60 ml/kg/day in dogs and 30-50 ml/kg/day in cats, adjusted for ongoing losses. For shock, administer 15-20 ml/kg IV bolus in dogs, 10-15 ml/kg in cats, repeated as needed. 2. Furosemide: 2-4 mg/kg IV, SC, or IM, q8-12h. Use with caution in hypovolemic patients. 3. Mannitol: 0.25-0.5 g/kg IV over 20 minutes, then 0.25-0.5 g/kg q4-6h if needed. Contraindicated in anuria or volume overload. 4. Hyperkalemia management: Calcium gluconate 10%: 0.5-1.0 ml/kg IV over 10-20 minutes, with ECG monitoring. Regular insulin: 0.1-0.2 U/kg IV, followed by dextrose 2 g per unit of insulin (e.g., 0.5-1 ml/kg of 50% dextrose diluted). Sodium bicarbonate: 1-2 mEq/kg IV over 15-30 minutes, only if pH <7.2. 5. Antiemetics: Maropitant (Cerenia): 1 mg/kg SC q24h, or 2 mg/kg PO q24h. Ondansetron: 0.5-1 mg/kg IV q12h. Metoclopramide: 1-2 mg/kg/day as CRI, or 0.2-0.4 mg/kg PO/SC q8h. 6. Gastroprotectants: Omeprazole: 0.5-1 mg/kg PO q12h. Sucralfate: 0.5-1 g PO q8h (dogs), 0.25-0.5 g PO q8h (cats). 7. Antibiotics for leptospirosis: Ampicillin: 20 mg/kg IV q8h for acute cases. Doxycycline: 5 mg/kg PO q12h for 14 days (after initial IV therapy). 8. Ethylene glycol antidotes: Ethanol 20% solution: 5.5 ml/kg IV q6h for 5 treatments, then q8h for 4 treatments. Fomepizole (4-methylpyrazole): 15 mg/kg IV initially, then 5 mg/kg at 12, 24, and 36 hours. 9. Nutritional support: If anorexic, consider enteral feeding via nasoesophageal or esophagostomy tube. Use a renal diet (low protein, low phosphorus) if azotemia persists. 10. Phosphate binders: Aluminum hydroxide (e.g., Amphojel): 30-100 mg/kg/day PO, divided q8-12h, to control hyperphosphatemia. 11. Erythropoietin: If anemia is severe (PCV <20%), consider recombinant human erythropoietin (100 U/kg SC three times weekly) or darbepoetin (1 μg/kg SC once weekly), but monitor for red cell aplasia. 12. Antihypertensives: If hypertension is present (systolic >160 mmHg), amlodipine (0.1-0.2 mg/kg PO q24h) or enalapril (0.5 mg/kg PO q12h) may be used. 13. Dialysis: Hemodialysis or peritoneal dialysis should be considered in severe AKI (IRIS grade IV or V) that is refractory to medical management. All dosages should be adjusted based on renal function and response to therapy.

The management of AKI in veterinary medicine is guided by consensus recommendations from the International Renal Interest Society (IRIS) and the American College of Veterinary Internal Medicine (ACVIM). The IRIS AKI grading scheme provides a standardized approach to staging and management. Key studies have evaluated the use of biomarkers such as SDMA and NGAL for early detection of AKI. A study by Nabity et al. (2015) demonstrated that SDMA is an earlier indicator of decreased GFR than creatinine in dogs with induced kidney disease. Another study by Segev et al. (2013) evaluated the use of urinary NGAL in dogs with AKI and found it to be a sensitive marker. Regarding treatment, a randomized controlled trial by Cowgill et al. (2013) evaluated the use of hemodialysis in dogs with AKI and found that early intervention improved survival. The use of furosemide in AKI has been debated; a study by Behrend et al. (2006) showed no benefit in terms of renal recovery. Leptospirosis is a common cause of AKI in dogs; a study by Goldstein et al. (2006) reported that early treatment with antibiotics and aggressive fluid therapy improved outcomes. For ethylene glycol toxicity, a study by Thrall et al. (1984) established the efficacy of fomepizole in dogs. In cats, lily toxicity is a well-known cause of AKI; a study by Rumbeiha et al. (2004) described the clinical course and treatment. Overall, the evidence supports early recognition, aggressive fluid therapy, and specific antidotes when available. The use of renal replacement therapy is recommended for severe cases, but it is not widely available. Further research is needed to evaluate novel therapeutic agents such as antioxidants and anti-inflammatory drugs in veterinary AKI.